Data as of Dec 18
| +3.00 / +2.14%|
The 20 analysts offering 12-month price forecasts for Valeant Pharmaceuticals have a median target of 166.50, with a high estimate of 182.00 and a low estimate of 132.00. The median estimate represents a +16.43% increase from the last price of 143.00.
The current consensus among 20 polled investment analysts is to Buy stock in Valeant Pharmaceuticals. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.